Klivira
Request demo

Streamlining Medicare Ultomiris Prior Authorization

Managing Medicare Ultomiris prior authorization can be a significant administrative burden for revenue cycle teams. Klivira streamlines this process, ensuring accurate and efficient submissions across relevant Medicare channels.

Ultomiris (ravulizumab) is a high-cost complement inhibitor often requiring prior authorization across various payer types, including Medicare. For healthcare organizations, understanding the nuanced prior authorization requirements for Ultomiris under Original Medicare (Parts A/B/D) and Medicare Advantage plans is critical for revenue integrity and patient access. Klivira's platform is designed to navigate these complexities.

Ultomiris and Medicare Coverage Considerations

Ultomiris is typically administered intravenously and falls under the medical benefit (Medicare Part B) when administered in an outpatient setting. For Original Medicare, prior authorization requirements for Part B drugs are limited compared to commercial or Medicare Advantage plans. However, specific services or drug categories may still necessitate PA. Medicare Advantage (Part C) plans, administered by private insurers, often have expanded prior authorization requirements for high-cost specialty drugs like Ultomiris, reflecting their specific formularies and utilization management policies.

Navigating Original Medicare Prior Authorization for Ultomiris

For Original Medicare (Fee-for-Service), where prior authorization for Ultomiris is required (e.g., if it falls under specific outpatient department services PA models or other limited programs), submissions are routed through the responsible Medicare Administrative Contractor (MAC) for the provider's jurisdiction. Klivira’s platform incorporates MAC-aware routing logic to ensure submissions are directed to the correct contractor, such as Noridian, NGS, WPS, Palmetto, FCSO, or Novitas, based on the service location.

Policy Adherence: NCDs and LCDs for Ultomiris

Klivira’s automation leverages National Coverage Determinations (NCDs) published by CMS and Local Coverage Determinations (LCDs) issued by individual MACs. For Ultomiris, any applicable NCDs or LCDs would define medical necessity criteria, dosage, and frequency. Our system incorporates this NCD/LCD-aware policy logic to help construct compliant prior authorization requests, ensuring that submitted documentation aligns with the payer's specific requirements.

Medicare Part D and Ultomiris (If Applicable)

While Ultomiris is typically a Part B drug, some specialty medications may fall under Medicare Part D (pharmacy benefit) if self-administered. For Part D plans, which are operated by commercial insurers, prior authorization protocols are governed by CMS-approved plan formularies and step-therapy requirements. Klivira supports the submission of pharmacy prior authorizations via NCPDP SCRIPT, integrating with the Part D plan's PBM or direct portal as needed.

Klivira's Role in Medicare Prior Authorization Automation

Klivira's platform streamlines prior authorization workflows for Ultomiris, whether under Original Medicare's limited PA scope or the more extensive requirements of Medicare Advantage plans. Our integration approach ensures that relevant clinical data from your EMR is automatically extracted and formatted for payer-specific submission channels, reducing manual effort and accelerating approval timelines. This includes supporting submissions through MAC portals and direct payer integrations.

Frequently asked questions

Does Original Medicare always require prior authorization for Ultomiris?

No, Original Medicare (Parts A/B) has a limited scope for prior authorization compared to Medicare Advantage plans. While Ultomiris is a high-cost drug, PA is typically only required if it falls under specific defined programs, such as certain outpatient department services PA models. Klivira helps identify and submit PA requests when required by the MAC.

How does Klivira handle Ultomiris PA for Medicare Advantage plans?

For Medicare Advantage plans, Klivira applies its full automation capabilities. We integrate with payer portals and utilize ePA standards to submit prior authorization requests for Ultomiris, adhering to the specific formulary, step-therapy, and medical necessity criteria of each private Medicare Advantage plan.

What information does Klivira use for Ultomiris prior authorization submissions to Medicare?

Klivira extracts relevant clinical documentation from your EMR, cross-referencing it against applicable National Coverage Determinations (NCDs) and Local Coverage Determinations (LCDs) for medical necessity. This ensures that the submission package for Ultomiris prior authorization is complete and compliant with Medicare's policy requirements.

Can Klivira integrate with my EMR for Ultomiris PA under Medicare?

Yes, Klivira integrates with major EMR systems using standards like SMART on FHIR. This allows for seamless data flow, automatically populating prior authorization forms for Ultomiris with patient demographics, diagnoses, and treatment plans, reducing manual data entry for your team.

Does Klivira help with appeals for Ultomiris denials from Medicare?

While Klivira focuses on optimizing initial prior authorization submissions to prevent denials, our platform also centralizes communication and documentation. This provides your team with the necessary information to efficiently manage and submit appeals for Ultomiris, leveraging a comprehensive audit trail of all prior authorization activities.

Related coverage

Other ultomiris prior authorization by payer

Other ultomiris prior authorization by specialty

Ready to automate prior auth for this drug?

See how Klivira automates prior authorizations for your team.

Request a demo